



Appendix B: Ongoing and Settled BPCIA Cases From 2024

Case Name	Court	Filing Date	Biosimilar at Issue	Reference Product at Issue	# Asserted Patents ¹	Status
<i>Regeneron v. Mylan, Biocon</i> (1:22-cv-00061)	N.D.W. Va.	8/2/2022	Yesafili™	Eylea®	24	Pending.
<i>Regeneron v. Celltrion</i> (1:23-cv-00089)	N.D.W. Va.	11/8/2023	CT-P42	Eylea®	38	Pending.
<i>Regeneron v. Samsung Bioepis</i> (1:23-cv-00094)	N.D.W. Va.	11/21/2023	Opuviz™	Eylea®	37	Pending.
<i>Regeneron v. Formycon</i> (1:23-cv-00097)	N.D.W. Va.	11/29/2023	Ahzantive®	Eylea®	39	Pending.
<i>Regeneron v. Samsung Bioepis</i> (1:23-cv-00106)	N.D.W. Va.	12/27/2023	Opuviz™	Eylea®	51	Pending.
<i>Regeneron v. Amgen</i> (1:24-cv-00039)	C.D. Cal./ N.D.W. Va. ²	1/10/2024	Pavblu™	Eylea®	32	Pending.
<i>Regeneron v. Celltrion</i> (1:24-cv-00053)	N.D.W. Va.	5/17/2024	CT-P42	Eylea®	25	Pending.
<i>Regeneron v. Sandoz</i> (1:24-cv-00085)	D.N.J./ N.D.W. Va. ³	8/26/2024	Enzeevu™	Eylea®	46	Pending.

¹ Patents asserted in the original complaints.

² This case was originally filed in the Central District of California with case number 2:24-cv-00264. In April 2024, the case was transferred to the Northern District of West Virginia and assigned case number 1:24-cv-00039.

³ This case was originally filed in the District of New Jersey with case number 2:24-cv-08760. In September 2024, the case was transferred to the Northern District of West Virginia and assigned case number 1:24-cv-00085.

Case Name	Court	Filing Date	Biosimilar at Issue	Reference Product at Issue	# Asserted Patents ¹	Status
<i>Biogen v. Sandoz, Polpharma</i> (1:22-cv-01190)	D. Del.	9/9/2022	Tyruko [®]	Tysabri [®]	28	Pending.
<i>Amgen v. Samsung Bioepis, Samsung Biologics</i> (1:24-cv-08417)	D.N.J.	8/12/2024	SB16	Prolia [®] and Xgeva [®]	34	Pending.
<i>Amgen v. Fresenius Kabi</i> (1:24-cv-09555)	N.D. Ill.	10/4/2024	FKS518	Prolia [®] and Xgeva [®]	33	Pending.
<i>Amgen v. Accord, Intas</i> (5:24-cv-00642)	E.D.N.C.	11/13/2024	INTP23	Prolia [®] and Xgeva [®]	34	Pending.
<i>Amgen v. Sandoz, Lek, Novartis</i> (1:23-cv-02406)	D.N.J.	5/1/2023	Jubbonti [®] and Wyost [®]	Prolia [®] and Xgeva [®]	21	Settled.
<i>Amgen v. Celltrion</i> (1:24-cv-06497)	D.N.J.	5/28/2024	CT-P41	Prolia [®] and Xgeva [®]	29	Settled.
<i>Genentech, Hoffmann-La Roche, Biogen v. Dr. Reddy's Laboratories, Fresenius Kabi</i> (1:23-cv-22485)	D.N.J.	11/17/2023	DRL_RI	Rituxan [®]	15	Settled.
<i>Alexion v. Samsung Bioepis</i> (1:24-cv-00005)	D. Del.	1/3/2024	Epysqli [®]	Soliris [®]	6	Settled.